Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery

American Journal of Respiratory Cell and Molecular Biology

Volumn 26, Issue 2, 2002, Pages 194-201

  Clapp, Lucie H ^a   Finney, Paul ^a   Turcato, Sally ^a   Tran, Sandy ^a   Rubin, Lewis J ^a   Tinker, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; BERAPROST; CICAPROST; CYCLIC AMP; DRUG DERIVATIVE; ENZYME INHIBITOR; ILOPROST; PLATELET DERIVED GROWTH FACTOR; PROSTACYCLIN; UNIPROST;

ARTICLE; CELL CULTURE; CELL DIVISION; CHEMICAL STRUCTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; PHYSIOLOGY; PULMONARY ARTERY; VASCULAR SMOOTH MUSCLE;

ADENYLATE CYCLASE; CELL DIVISION; CELLS, CULTURED; CYCLIC AMP; ENZYME INHIBITORS; EPOPROSTENOL; HUMANS; ILOPROST; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PULMONARY ARTERY;

EID: 0036007307     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/ajrcmb.26.2.4695     Document Type: Article

References (36)

1. Primary pulmonary hypertension
2. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
3. Nitric oxide and endothelin-1 in pulmonary hypertension
4. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
5. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: The Primary Pulmonary Hypertension Study Group
6. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
7. Prostanoid receptors: Structure, properties, and functions
8. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
9. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
10. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
11. Efficacy and safety of chronic subcutaneous infusion UT-15 in pulmonary arterial hypertension (PAH)
12. Iloprost: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures
13. Prostacyclin and atherosclerosis
14. Effects of beraprost sodium, a stable analogue of prostacyclin, on hyperplasia, hypertrophy and glycosaminoglycan synthesis of rat aortic smooth muscle cells
15. Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization
16. Prostacyclin synthase gene transfer inhibits neointimal formation in rat balloon-injured arteries without bleeding complications
17. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells
18. The effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cAMP elevation in isolated guinea-pig aorta
19. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers
20. U-61,431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells
21. Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs: Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents
22. 1 on DNA synthesis in vascular smooth muscle cells
23. 1 inhibits DNA synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor
24. Autocrine function of inducible nitric oxide synthase and cyclooxygenase-2 in proliferation of human and rat pulmonary artery smooth-muscle cells: Species variation
25. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
26. 3 receptor agonists on human isolated pulmonary artery
27. Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3′-polyphosphates
28. G protein regulation of adenylate cyclase
29. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics
30. Comparison of iloprost, cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets
31. Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics
32. Treatment of systemic sclerosis
33. 2 and selective EP agonists on chemotaxis of human neutrophils
34. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
35. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension
36. The pathology of hypertensive pulmonary vascular disease